Local Immunomodulation After Radiofrequency of Unresectable Colorectal Liver Metastases
Status:
Not yet recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
The main objective of this trial is to determine feasibility and tolerance of the human body
to RFA associated with local immunomodulation carried out using a thermoreversible hydrogel
combined with 2 immunomodulators, GMCSF and Mifamurtide.
The main endpoint of the study is the feasibility, the frequency and the nature of per and
post-operative adverse events of the in situ injection of an immunomodulatory hydrogel after
radiofrequency of unresectable colorectal liver metastases.
The secondary objective is one-year progression free survival rate.